The European Hematology Association Roadmap for European Hematology Research: a consensus document
Open Access
- 27 January 2016
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 101 (2), 115-208
- https://doi.org/10.3324/haematol.2015.136739
Abstract
The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.This publication has 171 references indexed in Scilit:
- Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010The Lancet, 2013
- RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidizationNature Communications, 2012
- The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors: a systematic reviewAnnals of Hematology, 2011
- Genome-wide Analysis of Simultaneous GATA1/2, RUNX1, FLI1, and SCL Binding in Megakaryocytes Identifies Hematopoietic RegulatorsDevelopmental Cell, 2011
- Bone progenitor dysfunction induces myelodysplasia and secondary leukaemiaNature, 2010
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- Constitutive hepcidin expression prevents iron overload in a mouse model of hemochromatosisNature Genetics, 2003
- Mutant antimicrobial peptide hepcidin is associated with severe juvenile hemochromatosisNature Genetics, 2002
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994